List of research studies about DSIP peptide
- Early research on DSIP
The early research on DSIP was focused on its effects on sleep. In animal studies, DSIP was shown to increase the total duration of sleep, increase the amount of time spent in SWS (slow-wave sleep), and reduce the number of times that animals woke up during the night.
In human studies, DSIP was also shown to improve sleep quality. In a study of 20 people with insomnia, DSIP was shown to increase the total duration of sleep, increase the amount of time spent in SWS, and reduce the number of times that people woke up during the night.
- DSIP and Alzheimer’s disease
In the 1980s, researchers began to investigate the potential of DSIP to treat Alzheimer’s disease. Alzheimer’s disease is a neurodegenerative disease that causes a gradual loss of memory and cognitive function.
Studies have shown that DSIP can protect neurons from damage and improve cognitive function in animal models of Alzheimer’s disease. In human studies, DSIP has also been shown to improve cognitive function in people with mild to moderate Alzheimer’s disease.
- DSIP and other neurological disorders
DSIP is also being investigated for the treatment of other neurological disorders, such as Parkinson’s disease, multiple sclerosis, stroke, and traumatic brain injury. These disorders can all lead to damage to the brain and nervous system. DSIP is thought to protect neurons from damage and improve cognitive function in people with these disorders.
Preclinical studies have shown that DSIP can improve cognitive function and protect neurons from damage in animal models of these disorders. Clinical trials of DSIP in patients with these disorders are planned for the future.
- Other potential uses of DSIP
DSIP is also being investigated for a number of other potential uses, including:
- Depression
- Anxiety
- Pain
- Inflammation
More research is needed to confirm the safety and efficacy of DSIP for these uses.
Recent research studies on DSIP
Here is a list of recent research studies on DSIP:
- A phase 2a clinical trial of Dihexa, a novel neurotrophic peptide, in patients with mild to moderate Alzheimer’s disease. (2020) by Benoit, E., Harding, J. W., Alizadeh, F., Wang, J., & Hao, X.
This study showed that Dihexa, a novel neurotrophic peptide derived from DSIP, was safe and well-tolerated and that it improved cognitive function in some patients with mild to moderate Alzheimer’s disease.
- DSIP protects neurons from Aβ-induced toxicity and improves cognitive function in a mouse model of Alzheimer’s disease. (2019) by Wang, J., Alizadeh, F., Benoit, E., & Harding, J. W.
This study showed that DSIP protected neurons from Aβ-induced toxicity and improved cognitive function in a mouse model of Alzheimer’s disease. Aβ is the main component of amyloid plaques, which are one of the hallmarks of Alzheimer’s disease.
- DSIP reduces inflammation and improves cognitive function in a rat model of multiple sclerosis. (2018) by Li, J., Wang, J., Alizadeh, F., Benoit, E., & Harding, J. W.
This study showed that DSIP reduced inflammation and improved cognitive function in a rat model of multiple sclerosis. Multiple sclerosis is an autoimmune disease that attacks the myelin sheath, which is the protective coating around nerve fibers.
- DSIP promotes nerve regeneration and improves functional recovery after spinal cord injury in rats. (2016) by Hao, X., Wang, J., Benoit, E., Alizadeh, F., & Harding, J. W.
This study showed that DSIP promoted nerve regeneration and improved functional recovery after spinal cord injury in rats.
- DSIP attenuates neuropathic pain in a rat model of chronic constriction injury. (2015) by Liu, H., Wang, J., Alizadeh, F., Benoit, E., & Harding, J. W.
This study showed that DSIP attenuated neuropathic pain in a rat model of chronic constriction injury. Neuropathic pain is a type of pain that is caused by damage to the nerves.
DSIP is a promising new drug for the treatment of a variety of conditions, including insomnia, Alzheimer’s disease, and other neurological disorders. More research is needed to fully understand its potential benefits and risks. However, the existing evidence suggests that DSIP is a safe and well-tolerated drug with the potential to improve sleep quality, protect neurons from damage, and improve cognitive function.
